Online inquiry

IVTScrip™ mRNA-Anti-LAG3, LAG-525(Cap 1, 2-Thio-UTP, 30 nt-poly(A))   (CAT#: GTTS-WQ10134MR)

This product GTTS-WQ10134MR is a type of mRNA having 30 nt poly(A) tail and modified with Cap 1 & 2-Thio-UTP. It ecodes the monoclonal antibody that targets LAG3 gene. The antibody can be applied in Solid tumors research.
Specifications
Product type mRNA
Modified bases 2-Thio-UTP
5' Cap Cap 1
Species Humanized
RefSeq NM_002286.6
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 3902
UniProt ID P18627
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-LAG3, LAG-525(Cap 1, 2-Thio-UTP, 30 nt-poly(A)) (GTTS-WQ10134MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ8782MR IVTScrip™ mRNA-Anti-PCSK9, IBI-306(Cap 1, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA IBI-306
GTTS-WQ13941MR IVTScrip™ mRNA-Anti-PDCD1, REGN-2810(Cap 0, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA REGN-2810
GTTS-WQ10967MR IVTScrip™ mRNA-Anti-IL17A&IL17F, MCAF-5352A(Cap 0, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA MCAF-5352A
GTTS-WQ935MR IVTScrip™ mRNA-Anti-EGFR, ABBV-321(Cap 0, 2-Thio-UTP, 120 nt-poly(A)) mRNA ABBV-321
GTTS-WQ1122MR IVTScrip™ mRNA-Anti-CD40, ABBV-927(Cap 1, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA ABBV-927
GTTS-WQ15401MR IVTScrip™ mRNA-Anti-HAVCR2, TSR-022(Cap 0, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA TSR-022
GTTS-WQ11532MR IVTScrip™ mRNA-Anti-CD3E, MGA031(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA MGA031
GTTS-WQ9578MR IVTScrip™ mRNA-Anti-EGFR&MET, JNJ-61186372(Cap 1, 2-Thio-UTP, 30 nt-poly(A)) mRNA JNJ-61186372
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW